Clinical trials: EGFR Overexpression
Carcinoma, Non-Small-Cell Lung
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway.
- Trial name
- NCT00294762
- Testing
- Tarceva, carboplatin, paclitaxel
- Where
- 43 sites in United States, United Kingdom
- Volunteers
- 143 people
- Sponsor
- OSI Pharmaceuticals
Neoplasms
Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2
To determine the maximum tolerated dose, safety, pharmacokinetics and anti-tumour efficacy of oral BIBW 2992 in combination with intravenous or oral vinorelbine
- Trial name
- NCT00906698
- Testing
- BIBW 2992 low (20mg) dosage, BIBW 2992 medium (40mg) dosage, BIBW 2992 high (50mg) dosage
- Where
- 2 sites in France
- Volunteers
- 55 people
- Sponsor
- Boehringer Ingelheim
Neoplasm, Gastrointestinal
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
The primary purpose of this trial is to compare the efficacy and safety of DS-8201a and physician's choice treatment in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed…
- Trial name
- NCT03329690
- Testing
- DS-8201a, Physician's Choice
- Where
- 66 sites in Japan, South Korea
- Volunteers
- 233 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Breast Cancer
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Eligible patients must receive Caelyx plus Cyclophosphamide plus Herceptin for 6 cycles that will be administered every 4 weeks.
- Trial name
- NCT00258960
- Testing
- Liposomal Doxorubicin, Cyclophosphamide, Trastuzumab
- Where
- 12 sites in Spain
- Volunteers
- 49 people
- Sponsor
- Spanish Breast Cancer Research Group
Neoplasms, Breast
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
This was a randomized, double-blind, placebo-controlled, multicenter, Phase III study to evaluate and compare the efficacy and safety of Lapatinib + Paclitaxel versus Placebo + Paclitaxel in men and women with ErbB2 amplified…
- Trial name
- NCT00281658
- Testing
- Lapatinib (GW572016) oral tablets, Paclitaxel infusion
- Where
- 54 sites in Brazil, China and 6 more
- Volunteers
- 444 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
This study will assess the efficacy and safety of intravenous (IV) trastuzumab (Herceptin) and IV docetaxel (Taxotere), with or without oral capecitabine (Xeloda), in women with previously untreated HER2-positive advanced and/or…
- Trial name
- NCT02748213
- Testing
- Xeloda, Taxotere, Herceptin
- Where
- 51 sites in Australia, Brazil and 13 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche